A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets
Biomolecules and Biomedicine · 2026
DOI: 10.17305/bb.2026.13832 ↗Kurz gefasst
Editorial in der Zeitschrift Biomolecules and Biomedicine, 2026. Verfasst von Krešimir Tomić und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Approval, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality worldwide; however, precision oncology has fundamentally transformed its treatment landscape. In 2025, seven approvals by the U.S. Food and Drug Administration (FDA) further accelerated biomarker-driven care across critical molecular subsets. These include MET-directed and trophoblast cell-surface antigen-2 (TROP-2) antibody-drug conjugates (ADCs), expanded strategies targeting epidermal growth factor receptor (EGFR), notably those addressing exon 20 insertion mutations, a ROS proto-oncogene 1 (ROS1) inhibitor, and various human epidermal growth factor receptor 2 (HER2) options that encompass both tumor-agnostic and mutation-selected approaches. These advancements underscore the necessity for integrated diagnostics—such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC)—while also emphasizing ongoing challenges in biomarker selection, therapeutic sequencing, and equitable global implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina.
- College of Medicine, QU Health, Qatar University, Doha, Qatar.
Zitieren
APA
Tomić, K., & Vranić, S. (2026). A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.13832
Vancouver
Tomić K, Vranić S. A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.13832
BibTeX
@article{Tomi2026,
author = {Tomić, Krešimir and Vranić, Semir},
title = {A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets},
journal = {Biomolecules and Biomedicine},
year = {2026},
doi = {10.17305/bb.2026.13832}
}
EUVIMED